-

Fresenius Kabi Introduces KabiCare Nutrition Resources for U.S. Parenteral Nutrition Products

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has introduced KabiCare Nutrition Resources in the United States as part of its KabiCare patient support program. The KabiCare Nutrition Resources program provides support for insurance reimbursement questions including a helpline staffed by experts to provide billing and coding support, insurance support such as benefit investigation, prior authorization and claims appeals. More information about KabiCare Nutrition Resources can be found at kabicare.us.

“Navigating the complexity of health insurance to provide access to critical parenteral nutrition products continues to be a challenge for some patients,” said Tom Tsilipetros, senior director, Market Access, at Fresenius Kabi USA. ”As a leader in parenteral nutrition, Fresenius Kabi’s goal with the KabiCare Nutrition Resources program in the U.S. is to help assure patients receive their care and parenteral nutrition products in as timely a manner, and as seamlessly, as possible.”

About KabiCare, a Patient Support Program

Fresenius Kabi created KabiCare, a Patient Support Program, to support patient access to products across numerous therapeutic areas. KabiCare provides a patient-centric approach which includes support and resources for eligible patients, caregivers, and health care providers throughout the treatment journey. For eligible patients, support may include navigating complex insurance processes as well as financial assistance. For additional information, please call 1-833-KABICARE or visit kabicare.us.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com/us/join-us and follow us on LinkedIn.

Contacts

Matt Kuhn
(847) 220-3033
matt.kuhn@fresenius-kabi.com

Industry:

Fresenius Kabi

Release Versions
English
Hashtags
#FreseniusKabi

Contacts

Matt Kuhn
(847) 220-3033
matt.kuhn@fresenius-kabi.com

Social Media Profiles
Fresenius Kabi USA
Fresenius Kabi USA on YouTube
More News From Fresenius Kabi

Fresenius Kabi and AABB Announce 21st Annual Blood Collectors Week, September 6–12, 2026, Honoring Lifesaving Blood Collection Professionals

LAKE ZURICH, Ill. & BETHESDA, Md.--(BUSINESS WIRE)--Fresenius Kabi and the Association for the Advancement of Blood & Biotherapies (AABB) announced today the launch of the 21st annual Blood Collectors Week, taking place September 6–12, 2026. The annual recognition week celebrates the blood collection professionals whose expertise and dedication help ensure patients across the country have access to safe, high-quality blood and blood components. Blood Collectors Week honors the essential pro...

Fresenius Kabi Launches Generic Sugammadex in Simplist® Ready‑to‑Administer Prefilled Syringe in the U.S.

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, a global healthcare company part of the Fresenius Group, specializing in lifesaving therapies and technologies, today announced the U.S. launch of the FDA‑approved generic Sugammadex Injection. Exclusivity for the branded medicine Bridion® (Merck) expired in July 2026. Fresenius Kabi offers operating room clinicians Sugammadex in a Simplist® ready-to-administer prefilled syringe. Simplist® single-dose, prefilled syringes require no assembly at...

Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 mL vials to the user level. An internal investigation at the firm found the product to contain glass particles. Risk Statement: The administration of an injectable product containing glass particulates may cause local irritation, pain, or swelling at the infusion site, as well as inflammation of the veins. More se...
Back to Newsroom